|
Market Cap (4-Jul) $86,511,600 (718th) |
Close (30-Jun) $0.63 |
Volume (30-Jun) 55,179 |
Shortsold (19-Jun) 190,561 (0.07%) (455th) |
|
52w High $0.57 |
52w Low $0.275 |
P/E - |
EPS -0.09 |
RCE released this announcement to the ASX on 7 September 2022, 10:01. The announcement is not marked as price sensitive, and is 28 page(s) in length and 4.56MB in size.
You can view all announcements from RCE and see how they appear on a price chart on the announcements page.
At the date of this announcement, RCE was 0.071% short sold according to ASIC data. It was ranked the 500th most shorted stock on the ASX. It is now ranked as the 455th most shorted stock on the ASX with 0.066% of total shares short sold as of the latest reported data (19 June 2025).
| Other Recent Announcements from RCE | |
|---|---|
| Ethics Approval for Phase I/II UTI Trial Expansion | 29 June 2023, 13:49 |
| Change of Director's Interest Notice - J Graham | 26 June 2023, 15:58 |
| DFI Clinical Trial Outpatient Nurses Appointed | 29 May 2023, 10:54 |
| Recce Delivers Opening R&D Address at World AMR Congress | 7 September 2022, 10:01 |
| RCE Appoints Dr John Prendergast as Executive Chairman | 5 September 2022, 10:06 |
| Initial Director's Interest Notice - A McKeough | 1 September 2022, 12:01 |
| Recce Appoints Alistair McKeough to Board of Directors | 1 September 2022, 11:58 |
You must be logged in to post a reply.
Recce Pharmaceuticals Ltd 